Preview Mode Links will not work in preview mode

Aug 31, 2023

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics:

  • Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00)
  • Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36)
  • Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14)
  • Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16)
  • Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23)

CME information and select publications